DMAE: Benefits, Evidence, and Why It's Not in the Formula

DMAE is an old-school nootropic that has been around for decades, often included in "focus" and anti-ageing products and promoted on the strength of a connection to acetylcholine, the memory neurotransmitter. It sounds plausible, and it has a long history of use — but the actual evidence is surprisingly thin and mixed, and there are some safety questions that count against it. This is an honest look at what DMAE is, where the evidence really stands, the considerations, and why Sharper Human supports acetylcholine through better-evidenced ingredients instead. This article is informational and not medical advice.

What DMAE Is

DMAE (dimethylaminoethanol, also called deanol) is a compound that occurs naturally in small amounts in the body and in foods such as fish. It has been used in supplements for decades, marketed for cognition, focus and mood, and it also appears in some skincare products for a claimed firming effect. The cognitive rationale rests on a proposed connection to acetylcholine — the neurotransmitter central to memory and attention — with the idea that DMAE might serve as a precursor or otherwise support acetylcholine production. It is, in short, an old and familiar nootropic with a plausible-sounding story. The problem, as so often, is that a plausible story and decades of use do not amount to good evidence.

The Evidence Is Thinner Than Its Reputation

For an ingredient that has been around so long, DMAE's evidence is surprisingly underwhelming. The proposed acetylcholine mechanism is not well confirmed — the simple "DMAE boosts acetylcholine" story is more assumed than demonstrated — and human studies on cognitive enhancement in healthy people are limited, dated and inconsistent, with no clear, robust demonstration of meaningful benefit. Much of its reputation rests on its long history and on older, weaker research rather than solid modern evidence. This places DMAE in the category of legacy nootropics: ingredients that persist in products largely through familiarity and inertia rather than because the data has caught up to justify them. Honest evaluation by the evidence, rather than by tradition, does not favour it.

The Cholinergic Comparison

The most useful way to assess DMAE is to compare it with the acetylcholine-supporting ingredients that do have good evidence. If the goal is to support the acetylcholine system, far better-evidenced options exist. Citicoline (CDP-choline) supplies choline for acetylcholine and has genuine human research on attention and cognition, with a clean safety profile suited to daily use; the citicoline guide covers it. Even at the potent end, Huperzine A has a clearer (if differently-mechanism) cholinergic action, though it requires cycling, as the Huperzine A guide explains. Against these, DMAE is the weakly-evidenced option for supporting the same system — which makes it hard to justify when better-supported choices are available. Choosing the better-evidenced cholinergic ingredient is simply the rational decision.

The Safety Questions

Beyond weak efficacy evidence, DMAE carries some safety considerations that further count against it. It is specifically advised against during pregnancy, with concerns relating to potential developmental effects, which is a significant red flag for any ingredient that might be taken by women of childbearing age. Reported side effects can include headaches, insomnia and overstimulation in some people. While DMAE is not generally considered acutely dangerous at typical doses for most adults, the combination of thin efficacy evidence and a pregnancy contraindication means there is little upside to weigh against the downsides. For a compound to earn a place in a daily formula taken by a broad audience, the risk-benefit balance has to be clearly favourable — and for DMAE it is not.

A Lesson in Evaluating Legacy Ingredients

DMAE is a useful case study in how to evaluate "classic" supplement ingredients rather than taking their longevity as proof. An ingredient being long-established and widely sold creates a powerful impression of credibility — surely something would not still be around after decades if it did not work? But persistence in the market is driven as much by familiarity, low cost and inertia as by evidence, and plenty of legacy ingredients have simply never been well validated even as the science around them moved on. The sensible approach is to judge any ingredient, old or new, by the same standard: what does the human evidence actually show, how plausible and confirmed is the mechanism, and what is the safety profile? Applied honestly, that standard leaves DMAE looking weak despite its history. This is the same discipline that runs through how a data-led formula selects ingredients — neither chasing the newest trendy compound nor coasting on the reputation of an old one, but following the evidence wherever it points. Longevity is not the same as proof, and treating it as such is how weak ingredients endure.

Why Sharper Human Doesn't Include It

Sharper Human · SH/001

Focus for Founders.

An all-natural brain performance supplement. 20 research-backed ingredients. No caffeine. No stimulants.

Buy on Amazon UK ↗

Sharper Human does not include DMAE, and the reasoning is straightforward: weak, mixed evidence combined with safety questions makes it a poor choice when better options exist for the same purpose. To support the acetylcholine system, Sharper Human uses Citicoline (300mg) — a choline donor with genuine human research on attention and cognition and a clean profile for daily use — supported by the broader formula including Lion's Mane (1000mg) and a full B-complex. Choosing the well-evidenced cholinergic ingredient over the legacy one, and avoiding a compound with a pregnancy contraindication in a broadly-used formula, is exactly the evidence-and-safety logic behind all 20 ingredients. DMAE is a good example of an ingredient that persists through reputation rather than merit, and that a data-led formula is right to leave out. The complete nootropics guide covers the better-evidenced ingredients to favour.

The honest bottom line: DMAE is an old, familiar nootropic with a plausible story but thin, mixed evidence and a pregnancy contraindication — so when better-evidenced acetylcholine support like Citicoline exists, a data-led formula is right to leave it out. Sharper Human is available on Amazon in the UK for around £79 per month, with US availability planned.